查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2106632

2034年獸醫腫瘤市場預測－全球分析（依動物種類、癌症類型、診斷方法、治療手段、給藥途徑、治療方案、最終使用者、通路和地區分類）

Veterinary Oncology Market Forecasts to 2034 - Global Analysis By Animal Type (Dogs, Cats, Horses, and Other Companion Animals), Cancer Type, Diagnosis, Treatment Type, Route of Administration, Therapy, End User, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球獸醫腫瘤市場規模將達到 19 億美元，並在預測期內以 12.6% 的複合年成長率成長，到 2034 年將達到 51 億美元。

獸醫腫瘤學是獸醫學的一個分支，專注於動物癌症的診斷、治療和管理。該市場涵蓋影像學（X光、超音波、CT、MRI、PET）、切片檢查和組織病理學、細胞學、分子診斷、免疫組織化學、臨床實驗室檢測以及其他診斷技術。治療方案包括化療、手術、放射療法、放射線治療、標靶治療、聯合治療和安寧療護。寵物數量的不斷成長、老年動物群體中癌症發病率的上升、對先進獸醫護理日益成長的需求以及診斷和治療方法的技術進步，是推動各地區市場擴張的主要因素。

寵物數量的增加和動物的老化

全球寵物數量的不斷成長以及老年動物罹患癌症風險的增加，是推動獸醫腫瘤學市場發展的主要因素。隨著獸醫學的進步和寵物壽命的延長，伴侶動物的癌症發生率也上升。寵物飼主越來越傾向於尋求專業的腫瘤治療服務，以延長寵物的壽命並提高其生活品質。寵物日益“擬人化”，使得人們更願意像對待人類醫療保健一樣，為寵物提供先進的癌症診斷和治療。隨著人們對獸醫腫瘤學治療方案的了解不斷加深，飼主也越來越重視全面的護理，因此，各個地區對癌症診斷和治療服務的需求都在持續成長。

治療費用高昂，保險覆蓋範圍有限。

獸醫腫瘤診斷和治療的高昂費用，加上寵物保險覆蓋範圍有限，是限制市場發展的主要阻礙因素。癌症治療，包括手術、化療和放射線治療，對許多寵物飼主來說可能難以承受。許多地區寵物保險覆蓋率低，迫使寵物主人承擔大量自付費用。獸醫醫院可能需要在腫瘤設備和專業人員方面投入大量資金，這會影響服務的可及性。這些費用障礙會限制寵物獲得先進腫瘤治療的機會，尤其對於低收入飼主和保險選擇有限的發展中地區而言更是如此。

診斷影像和分子診斷技術的進展

影像和分子診斷技術的持續創新為獸醫腫瘤市場的拓展帶來了巨大機會。 CT、MRI 和 PET 等先進影像技術能夠精準定位腫瘤、進行分期並制定治療方案。包括基因檢測和液態生物檢體的分子診斷技術能夠實現早期發現和個人化治療。免疫組織化學技術可用於腫瘤表徵，從而選擇標靶治療。人工智慧與影像技術的融合提高了觀察解讀的準確性。隨著診斷技術的普及和價格的降低，早期發現和精準治療方案的實施將擴大市場佔有率，並最終改善治療效果。

獸醫腫瘤學家和專業人員短缺

合格的獸醫腫瘤專家和訓練有素的輔助人員數量有限，對獸醫腫瘤市場構成重大威脅。獸醫腫瘤學需要超越一般獸醫教育的專業訓練。專家的短缺限制了服務的提供，尤其是在服務不足的地區和小規模動物醫院。有限的培訓計畫也會阻礙從業人員的成長。動物醫院可能難以招募合格的腫瘤專家來提供腫瘤服務。這種人員短缺會限制服務的擴展和患者的就診，這可能對市場成長和患者療效產生負面影響。

新型冠狀病毒（COVID-19）的影響：

新冠疫情對獸醫腫瘤市場產生了重大影響。初期，疫情封鎖期間動物醫院就診量下降，導致許多腫瘤相關預約延後。供應鏈中斷影響了診斷和治療所需材料的供應。然而，疫情期間寵物領養數量的激增和寵物數量的增加創造了新的患者群體。遠端醫療實現了遠距會診和後續觀察。寵物飼主在疫情期間將寵物的健康放在第一位。疫情過後，寵物數量的增加和人們對寵物健康的持續關注維持了對獸醫腫瘤服務的需求，動物醫院正在恢復並擴大其腫瘤相關服務。

在預測期內，醫療影像領域預計將佔據最大的市場佔有率。

預計在預測期內，診斷成像領域將佔據最大的市場佔有率。這主要歸功於診斷影像在所有腫瘤病例的癌症檢測、分期、治療計畫制定和後續觀察發揮的關鍵作用。 X光、超音波、CT、MRI和PET等診斷影像技術在獸醫腫瘤學實務中不可或缺。該領域受益於成熟技術的引入、持續的創新以及在各種臨床實踐中不斷擴展的應用。診斷影像通常是疑似癌症病例的首選診斷步驟，也是評估治療效果的關鍵。由於其重要的診斷作用以及在所有臨床環境中的廣泛應用，預計診斷影像將在整個預測期內保持診斷領域最大的市場佔有率。

在預測期內，「聯合治療」細分市場預計將呈現最高的複合年成長率。

在預測期內，聯合治療領域預計將呈現最高的成長率，這主要得益於多學科聯合治療方案療效顯著優於單一療法的證據不斷增加，以及結合手術、化療、放射線治療和免疫療法的綜合腫瘤治療方案的日益普及。與單一療法相比，聯合治療能夠顯著提高患者的存活率和生活品質。該領域受益於對癌症生物學特性和各種療法之間相互作用的深入了解。提供綜合腫瘤服務的獸醫專科中心數量的不斷增加，也促進了聯合療法的應用。隨著治療方案的不斷改進和綜合治療的標準化，聯合治療正在成為所有治療領域中成長最快的。

市佔率最大的地區：

在整個預測期內，北美預計將保持最大的市場佔有率，這主要得益於其較高的寵物擁有率、大量的獸醫護理支出以及先進的獸醫腫瘤學基礎設施。美國透過對專業獸醫服務的巨額投資，推動了區域市場的成長。認證獸醫腫瘤學家的存在以及先進治療設施的建設，為服務的提供提供了支持。寵物飼主對腫瘤治療方案的高度認知，也推動了市場需求。完善的寵物保險和資金籌措方案確保了寵物能夠獲得治療。憑藉高額的寵物相關支出和先進的腫瘤學基礎設施，北美在市場中保持主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於寵物擁有率的上升、可支配收入的增加以及中國、印度、日本和澳大利亞等國家對先進獸醫腫瘤服務的認知度不斷提高。該地區寵物擁有量的快速成長和中產階級的壯大，正在創造對獸醫專業服務的巨大需求。動物醫院的現代化和技術應用正在加速。獸醫教育和專科訓練投入的增加，正在拓展腫瘤診療系統。寵物飼主對癌症治療方案的認知度不斷提高，也推動了市場需求。隨著醫療保健的進步，亞太地區正經歷著全球成長最快的獸醫腫瘤市場。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球獸醫腫瘤市場：依動物類型分類

  • 狗
  • 貓
  • 馬
  • 其他伴侶動物

第6章 全球獸醫腫瘤市場：依癌症類型分類

  • 淋巴瘤
  • 肥大細胞癌
  • 骨癌
  • 乳腺腫瘤
  • 黑色素瘤
  • 軟組織肉瘤
  • 血管肉瘤
  • 鱗狀細胞癌
  • 移行細胞癌
  • 其他癌症

第7章：全球獸醫腫瘤市場：依診斷分類

  • 診斷影像
    • X光
    • 超音波檢查
    • 電腦斷層掃描（CT）
    • 磁振造影（MRI）
    • 正子斷層掃描（PET）
  • 切片檢查和組織病理學
  • 細胞學
  • 分子診斷
  • 免疫組織化學
  • 臨床試驗
  • 其他診斷方法

第8章：全球獸醫腫瘤市場：依治療類型分類

  • 化療
  • 外科手術
  • 放射線治療
  • 免疫療法
  • 標靶治療
  • 聯合治療
  • 安寧療護

第9章：全球獸醫腫瘤市場：依給藥途徑分類

  • 口服
  • 注射藥物
  • 外用

第10章 全球獸醫腫瘤市場：依療法分類

  • 藥物治療
  • 外科腫瘤學
  • 放射腫瘤學
  • 精準腫瘤學

第11章 全球獸醫腫瘤市場：依最終用戶分類

  • 動物醫院
  • 動物診所
  • 獸醫診斷檢測實驗室
  • 獸醫學術和研究機構

第12章：全球獸醫腫瘤市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 直銷

第13章 全球獸醫腫瘤市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第14章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第15章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品上市及法規核准
  • 擴大生產能力和投資
  • 其他策略舉措

第16章：公司簡介

  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Merck Animal Health
  • Boehringer Ingelheim Animal Health
  • Virbac SA
  • Dechra Pharmaceuticals PLC
  • IDEXX Laboratories, Inc.
  • Antech Diagnostics, Inc.
  • VolitionRx Limited
  • Torigen Pharmaceuticals Inc.
  • PetCure Oncology
  • Varian Medical Systems, Inc.
  • Accuray Incorporated
  • FidoCure（One Health Company）
  • ImpriMed, Inc.
  • Regeneus Ltd.
Product Code: SMRC38705

According to Stratistics MRC, the Global Veterinary Oncology Market is accounted for $1.9 billion in 2026 and is expected to reach $5.1 billion by 2034 growing at a CAGR of 12.6% during the forecast period. Veterinary oncology is a specialized branch of veterinary medicine focused on the diagnosis, treatment, and management of cancer in animals. The market encompasses diagnostic methods including imaging (X-ray, ultrasound, CT, MRI, PET), biopsy and histopathology, cytology, molecular diagnostics, immunohistochemistry, laboratory tests, and other diagnostic approaches. Treatment modalities include chemotherapy, surgery, radiation therapy, immunotherapy, targeted therapy, combination therapy, and palliative care. Growing pet ownership, increasing prevalence of cancer in aging animal populations, rising demand for advanced veterinary care, and technological advancements in diagnostic and treatment modalities are key drivers of market expansion across all regions.

Market Dynamics:

Driver:

Increasing pet ownership and aging animal populations

The rising global pet population and the growing number of aging animals susceptible to cancer are primary drivers for the veterinary oncology market. As veterinary care advances and pets live longer, the incidence of cancer in companion animals is increasing. Pet owners are increasingly seeking specialized oncology services to extend their pets' lives and improve quality of life. The humanization of pets has led to greater willingness to invest in advanced cancer diagnostics and treatments comparable to human healthcare. As awareness of veterinary oncology options expands and pet owners prioritize comprehensive care, demand for cancer diagnosis and treatment services continues growing across all regions.

Restraint:

High treatment costs and limited insurance coverage

The significant costs associated with veterinary oncology diagnosis and treatment and limited pet insurance coverage represent a major restraint for the market. Cancer treatment including surgery, chemotherapy, and radiation therapy can be prohibitively expensive for many pet owners. Limited pet insurance penetration in many regions leaves owners responsible for substantial out-of-pocket expenses. Veterinary practices may require significant investment in oncology equipment and specialized staff, affecting service availability. These cost barriers may limit access to advanced oncology care, particularly for lower-income pet owners and in developing regions with limited insurance options.

Opportunity:

Advancements in diagnostic imaging and molecular diagnostics

Continuous innovation in diagnostic imaging and molecular diagnostic technologies presents significant opportunities for veterinary oncology market expansion. Advanced imaging including CT, MRI, and PET enables precise tumor localization, staging, and treatment planning. Molecular diagnostics including genetic testing and liquid biopsies enable early detection and personalized treatment approaches. Immunohistochemistry enables tumor characterization for targeted therapy selection. Integration of AI in diagnostic imaging enhances interpretation accuracy. As diagnostic technologies become more accessible and affordable, early detection and precise treatment planning capture growing market share, enabling improved outcomes.

Threat:

Shortage of veterinary oncologists and specialists

The limited availability of board-certified veterinary oncologists and trained support staff poses significant threats to the veterinary oncology market. Veterinary oncology requires specialized training beyond general veterinary education. The shortage of specialists restricts service availability, particularly in underserved areas and smaller practices. Limited training programs may constrain workforce growth. Veterinary practices may struggle to recruit qualified oncologists to staff oncology services. This workforce shortage may limit service expansion and patient access, potentially affecting market growth and patient outcomes.

Covid-19 Impact:

The COVID-19 pandemic had a significant impact on the veterinary oncology market. Initial disruptions included reduced veterinary visits during lockdowns, with many oncology appointments postponed. Supply chain interruptions affected diagnostic and treatment supplies. However, pet adoption surged during the pandemic, expanding the pet population and creating new patients. Telemedicine enabled remote consultations and follow-up care. Pet owners prioritized pet health during the crisis. Post-pandemic, elevated pet ownership and continued focus on pet health have sustained demand for veterinary oncology services, with practices resuming and expanding oncology offerings.

The Imaging segment is expected to be the largest during the forecast period

The Imaging segment is expected to account for the largest market share during the forecast period, driven by the essential role of diagnostic imaging in cancer detection, staging, treatment planning, and monitoring across all oncology cases. Imaging modalities including X-ray, ultrasound, CT, MRI, and PET are fundamental to veterinary oncology practice. The segment benefits from established technology adoption, continuous innovation, and expanding availability across practice types. Imaging is often the first diagnostic step in suspected cancer cases and is essential for evaluating treatment response. With essential diagnostic role and broad adoption across practice settings, imaging maintains the largest diagnostic segment share throughout the forecast period.

The Combination Therapy segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Combination Therapy segment is predicted to witness the highest growth rate, fueled by growing evidence of superior outcomes from multimodal treatment approaches and increasing adoption of integrated oncology protocols combining surgery, chemotherapy, radiation, and immunotherapy. Combination therapy offers improved survival rates and quality of life compared to single-modality treatment. The segment benefits from advances in understanding cancer biology and treatment interactions. Growing veterinary specialty centers offering comprehensive oncology services drive adoption. As treatment protocols evolve and integrated care becomes standard, combination therapy delivers the fastest treatment segment growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by high pet ownership rates, strong spending on veterinary care, and advanced veterinary oncology infrastructure. The United States leads regional market growth with substantial investment in specialty veterinary services. Availability of board-certified veterinary oncologists and advanced treatment facilities supports service provision. High awareness of oncology treatment options among pet owners drives demand. Established pet insurance and financing options enable treatment access. With high pet spending and advanced oncology infrastructure, North America maintains its dominant market position.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by rising pet ownership, increasing disposable incomes, and growing awareness of advanced veterinary oncology services across countries including China, India, Japan, and Australia. The region's rapidly growing pet population and expanding middle class create substantial demand for veterinary specialty services. Veterinary practice modernization and technology adoption are accelerating. Increasing investment in veterinary education and specialist training expands oncology capacity. Growing awareness of cancer treatment options among pet owners drives demand. As veterinary healthcare develops, Asia Pacific delivers the fastest veterinary oncology market growth globally.

Key players in the market

Some of the key players in Veterinary Oncology Market include Zoetis Inc., Elanco Animal Health Incorporated, Merck Animal Health, Boehringer Ingelheim Animal Health, Virbac S.A., Dechra Pharmaceuticals PLC, IDEXX Laboratories, Inc., Antech Diagnostics, Inc., VolitionRx Limited, Torigen Pharmaceuticals Inc., PetCure Oncology, Varian Medical Systems, Inc., Accuray Incorporated, FidoCure (One Health Company), ImpriMed, Inc., and Regeneus Ltd.

Key Developments:

In March 2026, Torigen Pharmaceuticals detailed the regulatory evolution of its point-of-care autologous cancer vaccine, VimClara, moving to a 9 CFR 107.1 in-clinic preparation kit classification that allows veterinarians to create personalized immunotherapies from excised tumor tissue in roughly 40 minutes.

In February 2026, Zoetis completed the acquisition of Veterinary Pathology Group (VPG) to expand its multi-specialty diagnostic services, enhancing specialized oncology pathology support and fast-turnaround diagnostic insights for veterinary practices.

In January 2026, VolitionRx announced breakthrough clinical results for its Nu.Q(R) Vet Feline assay, demonstrating over 80% sensitivity at 100% specificity for detecting feline lymphoma, paving the way for the world's first blood-based liquid biopsy test for cat cancer.

In September 2025, IDEXX Laboratories presented clinical data at the Veterinary Cancer Society Annual Conference highlighting its IDEXX Cancer Dx(TM) blood test, which detected circulating biomarkers for canine lymphoma up to 6 to 8 months prior to the onset of clinical signs.

Animal Types Covered:

  • Dogs
  • Cats
  • Horses
  • Other Companion Animals

Cancer Types Covered:

  • Lymphoma
  • Mast Cell Cancer
  • Osteosarcoma
  • Mammary Gland Tumors
  • Melanoma
  • Soft Tissue Sarcoma
  • Hemangiosarcoma
  • Squamous Cell Carcinoma
  • Transitional Cell Carcinoma
  • Other Cancer Types

Diagnosis Types Covered:

  • Imaging
  • Biopsy and Histopathology
  • Cytology
  • Molecular Diagnostics
  • Immunohistochemistry
  • Laboratory Tests
  • Other Diagnostic Methods

Treatment Types Covered:

  • Chemotherapy
  • Surgery
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy
  • Combination Therapy
  • Palliative Care

Routes of Administration Covered:

  • Oral
  • Injectable
  • Topical

Therapies Covered:

  • Drug Therapy
  • Surgical Oncology
  • Radiation Oncology
  • Precision Oncology

End Users Covered:

  • Veterinary Hospitals
  • Veterinary Clinics
  • Veterinary Diagnostic Laboratories
  • Veterinary Academic and Research Institutes

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Direct Sales

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Veterinary Oncology Market, By Animal Type

  • 5.1 Dogs
  • 5.2 Cats
  • 5.3 Horses
  • 5.4 Other Companion Animals

6 Global Veterinary Oncology Market, By Cancer Type

  • 6.1 Lymphoma
  • 6.2 Mast Cell Cancer
  • 6.3 Osteosarcoma
  • 6.4 Mammary Gland Tumors
  • 6.5 Melanoma
  • 6.6 Soft Tissue Sarcoma
  • 6.7 Hemangiosarcoma
  • 6.8 Squamous Cell Carcinoma
  • 6.9 Transitional Cell Carcinoma
  • 6.10 Other Cancer Types

7 Global Veterinary Oncology Market, By Diagnosis

  • 7.1 Imaging
    • 7.1.1 X-ray
    • 7.1.2 Ultrasound
    • 7.1.3 Computed Tomography (CT)
    • 7.1.4 Magnetic Resonance Imaging (MRI)
    • 7.1.5 Positron Emission Tomography (PET)
  • 7.2 Biopsy and Histopathology
  • 7.3 Cytology
  • 7.4 Molecular Diagnostics
  • 7.5 Immunohistochemistry
  • 7.6 Laboratory Tests
  • 7.7 Other Diagnostic Methods

8 Global Veterinary Oncology Market, By Treatment Type

  • 8.1 Chemotherapy
  • 8.2 Surgery
  • 8.3 Radiation Therapy
  • 8.4 Immunotherapy
  • 8.5 Targeted Therapy
  • 8.6 Combination Therapy
  • 8.7 Palliative Care

9 Global Veterinary Oncology Market, By Route of Administration

  • 9.1 Oral
  • 9.2 Injectable
  • 9.3 Topical

10 Global Veterinary Oncology Market, By Therapy

  • 10.1 Drug Therapy
  • 10.2 Surgical Oncology
  • 10.3 Radiation Oncology
  • 10.4 Precision Oncology

11 Global Veterinary Oncology Market, By End User

  • 11.1 Veterinary Hospitals
  • 11.2 Veterinary Clinics
  • 11.3 Veterinary Diagnostic Laboratories
  • 11.4 Veterinary Academic and Research Institutes

12 Global Veterinary Oncology Market, By Distribution Channel

  • 12.1 Hospital Pharmacies
  • 12.2 Retail Pharmacies
  • 12.3 Online Pharmacies
  • 12.4 Direct Sales

13 Global Veterinary Oncology Market, By Geography

  • 13.1 North America
    • 13.1.1 United States
    • 13.1.2 Canada
    • 13.1.3 Mexico
  • 13.2 Europe
    • 13.2.1 United Kingdom
    • 13.2.2 Germany
    • 13.2.3 France
    • 13.2.4 Italy
    • 13.2.5 Spain
    • 13.2.6 Netherlands
    • 13.2.7 Belgium
    • 13.2.8 Sweden
    • 13.2.9 Switzerland
    • 13.2.10 Poland
    • 13.2.11 Rest of Europe
  • 13.3 Asia Pacific
    • 13.3.1 China
    • 13.3.2 Japan
    • 13.3.3 India
    • 13.3.4 South Korea
    • 13.3.5 Australia
    • 13.3.6 Indonesia
    • 13.3.7 Thailand
    • 13.3.8 Malaysia
    • 13.3.9 Singapore
    • 13.3.10 Vietnam
    • 13.3.11 Rest of Asia Pacific
  • 13.4 South America
    • 13.4.1 Brazil
    • 13.4.2 Argentina
    • 13.4.3 Colombia
    • 13.4.4 Chile
    • 13.4.5 Peru
    • 13.4.6 Rest of South America
  • 13.5 Rest of the World (RoW)
    • 13.5.1 Middle East
      • 13.5.1.1 Saudi Arabia
      • 13.5.1.2 United Arab Emirates
      • 13.5.1.3 Qatar
      • 13.5.1.4 Israel
      • 13.5.1.5 Rest of Middle East
    • 13.5.2 Africa
      • 13.5.2.1 South Africa
      • 13.5.2.2 Egypt
      • 13.5.2.3 Morocco
      • 13.5.2.4 Rest of Africa

14 Strategic Market Intelligence

  • 14.1 Industry Value Network and Supply Chain Assessment
  • 14.2 White-Space and Opportunity Mapping
  • 14.3 Product Evolution and Market Life Cycle Analysis
  • 14.4 Channel, Distributor, and Go-to-Market Assessment

15 Industry Developments and Strategic Initiatives

  • 15.1 Mergers and Acquisitions
  • 15.2 Partnerships, Alliances, and Joint Ventures
  • 15.3 New Product Launches and Regulatory Approvals
  • 15.4 Capacity Expansion and Investments
  • 15.5 Other Strategic Initiatives

16 Company Profiles

  • 16.1 Zoetis Inc.
  • 16.2 Elanco Animal Health Incorporated
  • 16.3 Merck Animal Health
  • 16.4 Boehringer Ingelheim Animal Health
  • 16.5 Virbac S.A.
  • 16.6 Dechra Pharmaceuticals PLC
  • 16.7 IDEXX Laboratories, Inc.
  • 16.8 Antech Diagnostics, Inc.
  • 16.9 VolitionRx Limited
  • 16.10 Torigen Pharmaceuticals Inc.
  • 16.11 PetCure Oncology
  • 16.12 Varian Medical Systems, Inc.
  • 16.13 Accuray Incorporated
  • 16.14 FidoCure (One Health Company)
  • 16.15 ImpriMed, Inc.
  • 16.16 Regeneus Ltd.

List of Tables

  • Table 1 Global Veterinary Oncology Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Veterinary Oncology Market Outlook, By Animal Type (2023-2034) ($MN)
  • Table 3 Global Veterinary Oncology Market Outlook, By Dogs (2023-2034) ($MN)
  • Table 4 Global Veterinary Oncology Market Outlook, By Cats (2023-2034) ($MN)
  • Table 5 Global Veterinary Oncology Market Outlook, By Horses (2023-2034) ($MN)
  • Table 6 Global Veterinary Oncology Market Outlook, By Other Companion Animals (2023-2034) ($MN)
  • Table 7 Global Veterinary Oncology Market Outlook, By Cancer Type (2023-2034) ($MN)
  • Table 8 Global Veterinary Oncology Market Outlook, By Lymphoma (2023-2034) ($MN)
  • Table 9 Global Veterinary Oncology Market Outlook, By Mast Cell Cancer (2023-2034) ($MN)
  • Table 10 Global Veterinary Oncology Market Outlook, By Osteosarcoma (2023-2034) ($MN)
  • Table 11 Global Veterinary Oncology Market Outlook, By Mammary Gland Tumors (2023-2034) ($MN)
  • Table 12 Global Veterinary Oncology Market Outlook, By Melanoma (2023-2034) ($MN)
  • Table 13 Global Veterinary Oncology Market Outlook, By Soft Tissue Sarcoma (2023-2034) ($MN)
  • Table 14 Global Veterinary Oncology Market Outlook, By Hemangiosarcoma (2023-2034) ($MN)
  • Table 15 Global Veterinary Oncology Market Outlook, By Squamous Cell Carcinoma (2023-2034) ($MN)
  • Table 16 Global Veterinary Oncology Market Outlook, By Transitional Cell Carcinoma (2023-2034) ($MN)
  • Table 17 Global Veterinary Oncology Market Outlook, By Other Cancer Types (2023-2034) ($MN)
  • Table 18 Global Veterinary Oncology Market Outlook, By Diagnosis (2023-2034) ($MN)
  • Table 19 Global Veterinary Oncology Market Outlook, By Imaging (2023-2034) ($MN)
  • Table 20 Global Veterinary Oncology Market Outlook, By X-ray (2023-2034) ($MN)
  • Table 21 Global Veterinary Oncology Market Outlook, By Ultrasound (2023-2034) ($MN)
  • Table 22 Global Veterinary Oncology Market Outlook, By Computed Tomography (CT) (2023-2034) ($MN)
  • Table 23 Global Veterinary Oncology Market Outlook, By Magnetic Resonance Imaging (MRI) (2023-2034) ($MN)
  • Table 24 Global Veterinary Oncology Market Outlook, By Positron Emission Tomography (PET) (2023-2034) ($MN)
  • Table 25 Global Veterinary Oncology Market Outlook, By Biopsy and Histopathology (2023-2034) ($MN)
  • Table 26 Global Veterinary Oncology Market Outlook, By Cytology (2023-2034) ($MN)
  • Table 27 Global Veterinary Oncology Market Outlook, By Molecular Diagnostics (2023-2034) ($MN)
  • Table 28 Global Veterinary Oncology Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 29 Global Veterinary Oncology Market Outlook, By Laboratory Tests (2023-2034) ($MN)
  • Table 30 Global Veterinary Oncology Market Outlook, By Other Diagnostic Methods (2023-2034) ($MN)
  • Table 31 Global Veterinary Oncology Market Outlook, By Treatment Type (2023-2034) ($MN)
  • Table 32 Global Veterinary Oncology Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 33 Global Veterinary Oncology Market Outlook, By Surgery (2023-2034) ($MN)
  • Table 34 Global Veterinary Oncology Market Outlook, By Radiation Therapy (2023-2034) ($MN)
  • Table 35 Global Veterinary Oncology Market Outlook, By Immunotherapy (2023-2034) ($MN)
  • Table 36 Global Veterinary Oncology Market Outlook, By Targeted Therapy (2023-2034) ($MN)
  • Table 37 Global Veterinary Oncology Market Outlook, By Combination Therapy (2023-2034) ($MN)
  • Table 38 Global Veterinary Oncology Market Outlook, By Palliative Care (2023-2034) ($MN)
  • Table 39 Global Veterinary Oncology Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 40 Global Veterinary Oncology Market Outlook, By Oral (2023-2034) ($MN)
  • Table 41 Global Veterinary Oncology Market Outlook, By Injectable (2023-2034) ($MN)
  • Table 42 Global Veterinary Oncology Market Outlook, By Topical (2023-2034) ($MN)
  • Table 43 Global Veterinary Oncology Market Outlook, By Therapy (2023-2034) ($MN)
  • Table 44 Global Veterinary Oncology Market Outlook, By Drug Therapy (2023-2034) ($MN)
  • Table 45 Global Veterinary Oncology Market Outlook, By Surgical Oncology (2023-2034) ($MN)
  • Table 46 Global Veterinary Oncology Market Outlook, By Radiation Oncology (2023-2034) ($MN)
  • Table 47 Global Veterinary Oncology Market Outlook, By Precision Oncology (2023-2034) ($MN)
  • Table 48 Global Veterinary Oncology Market Outlook, By End User (2023-2034) ($MN)
  • Table 49 Global Veterinary Oncology Market Outlook, By Veterinary Hospitals (2023-2034) ($MN)
  • Table 50 Global Veterinary Oncology Market Outlook, By Veterinary Clinics (2023-2034) ($MN)
  • Table 51 Global Veterinary Oncology Market Outlook, By Veterinary Diagnostic Laboratories (2023-2034) ($MN)
  • Table 52 Global Veterinary Oncology Market Outlook, By Veterinary Academic and Research Institutes (2023-2034) ($MN)
  • Table 53 Global Veterinary Oncology Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 54 Global Veterinary Oncology Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 55 Global Veterinary Oncology Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 56 Global Veterinary Oncology Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 57 Global Veterinary Oncology Market Outlook, By Direct Sales (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.